Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, placebo-controlled study of 2LEBV and 2LXFS/2LEBV for asthenia in EBV infection
2020-000085-42Phase 4Active
- Sponsor
- Labo'Life Belgium
- Start
- Aug 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Epstein-Barr virus infection and asthenia comparing 2LEBV, 2LXFS/2LEBV and Placebo (3 arms). Primary endpoint: General fatigue (MFI-20) at end of treatment. Started Aug 2020; status: active.
02
Drugs
2LEBV2LXFS
03
Conditions
Epstein-Barr virus infectionasthenia
Beyond the preview
Go deeper on 2020-000085-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000085-42.